- Category
- Micro (2021-22)
- Udyam number
- UDYAM-TS-02-0033254

Ynr Laboratories Private Limited
About Ynr Laboratories Private Limited
Data last updated:
Ynr Laboratories Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 July 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24304TG2021PTC152774. Its GSTIN is 36AABCY4035D1ZL (Telangana).
The company has an authorised share capital of ₹3.11 Cr and a paid-up capital of ₹3.11 Cr. It is led by directors Chaitanya Gudipati and Yarram Narasimha Reddy.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at P. No – 16 Ida Nacharam Cfc Area Industrial Park, Hyderabad, Telangana, India – 500076.
As per the financials filed for FY 2024, the company reported a revenue of ₹26.04 Lakh. For the same year it recorded a net profit of ₹58,756 (net margin 2.3%) and EBITDA of ₹58,756 (EBITDA margin 2.3%).
As per MCA filings, the company has open charges of ₹3.93 Cr on record.
Ynr Laboratories Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0033254).
Company details
Recognitions & Rankings of Ynr Laboratories
Contact details
Ynr Laboratories Private Limited's registered office is in Hyderabad, Telangana. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressP. No – 16 Ida Nacharam Cfc Area Industrial Park, Hyderabad, Telangana, India – 500076
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Ynr Laboratories Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ynr Laboratories is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Ynr Laboratories Private Limited, buy the company report.
Financials of Ynr Laboratories Private Limited
FY 2025 filings availableYnr Laboratories Private Limited reported revenue of ₹26.04 Lakh for FY 2024.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹58,756 | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹58,756 | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 2.3% | ||
| Net Profit Margin | 2.3% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Ynr Laboratories Private Limited, buy the company report.
Board of directors of Ynr Laboratories Private Limited
Ynr Laboratories has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chaitanya Gudipati | Director | 02 Jul 2021 | 5 Years 4 Months | Current |
| Yarram Narasimha Reddy Also directs: Nchem Laboratories Private Limited | Director | 02 Jul 2021 | 5 Years 4 Months | Current |
Peer comparison
Ynr Laboratories Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| PRBL Medimpex Private Limited | ₹26.71 Lakh (FY 2025) | 1.0% | Thane, Maharashtra, India | |||
| Vishakha Criticare Solutions Private Limited | ₹26.66 Lakh (FY 2025) | 1136.0% | Chennai, Tamil Nadu, India | |||
| Velesila Pharmaceuticals Private Limited | ₹26.14 Lakh (FY 2025) | 101.0% | Bahadurgarh, Haryana, India | |||
| Bengal Research & Chemical Laboratory Pvt Ltd | ₹26.14 Lakh (FY 2025) | -9.0% | Kolkata, West Bengal, India | |||
| Progressive Molecules Private Limited | ₹26.09 Lakh (FY 2025) | 2819.0% | Cachar, Assam, India | |||
| Ynr Laboratories Private Limitedthis company | ₹26.04 Lakh (FY 2024) | ₹58,756 | 2.3% | Hyderabad, Telangana, India | ||
| Resincoats Private Limited | ₹26 Lakh (FY 2025) | -70.0% | Indore, Madhya Pradesh, India | |||
| Bionex Vetcare Private Limited | ₹26 Lakh (FY 2025) | 24.0% | Thane, Maharashtra, India | |||
| Lifeset Pharma Private Limited | ₹25.93 Lakh (FY 2025) | 82.0% | Purnia, Bihar, India | |||
| Shasari Healthcare India Private Limited | ₹25.71 Lakh (FY 2025) | Noida, Uttar Pradesh, India | ||||
| Medisson Healthcare Solutions Private Limited | ₹25.53 Lakh (FY 2025) | -51.0% | Vaishali Nagar, Jaipur, Rajasthan, India |
To see the full peer comparison of Ynr Laboratories Private Limited, buy the company report.
Auditor
Ynr Laboratories Private Limited is audited by G V M K & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| G V M K & CO | FY 2023 | 025868S |
Shareholding
The shareholding of Ynr Laboratories Private Limited is on record for 2 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Ynr Laboratories Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Jul 2024 | 100959510 | Others | ₹3.93 Cr | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Ynr Laboratories Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ynr Laboratories Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Ynr Laboratories Private Limited has 1 active EPFO establishment as of Mar 28, 2024.
GST
Ynr Laboratories has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCY4035D1ZL | Telangana | Active | 19 Apr 2022 |
To see the full GST registrations and return filing status of Ynr Laboratories Private Limited, buy the company report.
Recent activity
Ynr Laboratories Private Limited has 2 board changes on record since 2021: 2 appointments. The latest: Chaitanya Gudipati was appointed as Director on 02 Jul 2021.
Frequently asked questions
Ynr Laboratories is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 July 2021 (5+ years old) and is registered under CIN U24304TG2021PTC152774.
Ynr Laboratories has 2 current directors:
- Chaitanya Gudipati - Director
- Yarram Narasimha Reddy - Director
The latest financial statements of Ynr Laboratories on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Ynr Laboratories is 36AABCY4035D1ZL, registered in Telangana.
The CIN (Corporate Identification Number) of Ynr Laboratories is U24304TG2021PTC152774. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ynr Laboratories was incorporated on 02 July 2021, making it 5+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Ynr Laboratories by revenue are PRBL Medimpex Private Limited, Vishakha Criticare Solutions Private Limited, Velesila Pharmaceuticals Private Limited, Bengal Research & Chemical Laboratory Pvt Ltd, Progressive Molecules Private Limited and 5 more, all in the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).
Chaitanya Gudipati was appointed as Director on 02 Jul 2021. Yarram Narasimha Reddy was appointed as Director on 02 Jul 2021.
Yes, Ynr Laboratories is registered as a micro enterprise under Udyam registration (number: UDYAM-TS-02-0033254).
The registered office of Ynr Laboratories is at P. No – 16 Ida Nacharam Cfc Area Industrial Park, Hyderabad, Telangana, India – 500076.
Ynr Laboratories operates in the pharma industry, in the drug formulation and development segment.

